Garin E, Denizot B, Roux J, Noiret N, Lepareur N, Moreau M, Mesba H, Laurent J F, Herry J Y, Bourguet P, Benoit J P, Lejeune J J
UPRES EA 1794/Service de Médecine Nucléaire, Centre Eugène Marquis, Rennes, France.
Lab Anim. 2005 Jul;39(3):314-20. doi: 10.1258/0023677054307051.
Intra-arterial metabolic radiotherapy (using lipiodol labelled with iodine-131 or rhenium-188) is a therapeutic approach that can be used for the treatment of hepatocellular carcinomas (HCC). We propose a detailed description of the tumoral model using the N1-S1 cell line as well as a technique for intra-arterial injection of radiolabelled lipiodol in order to undertake preclinical studies necessary for the evaluation of a new molecule. We also report the principal technical pitfalls that were faced. The speed of injection of the tumoral cells is a key factor in the tumoral induction since slow injections lead to a tumoral induction rate of 36.3% compared with 76.6% (P<0.01) when using very slow injections. This parameter should thus be controlled carefully during the subcapsular injection of the tumoral cells. In addition, when injecting radiolabelled lipiodol, anaesthesia should not be performed with isoflurane since this leads to a reduction in tumoral uptake. Indeed, we found a 'tumour/healthy liver' uptake ratio of only 2.1+/-0.7 with isoflurane as against 4.4+/-2.6 (P<0.05) when anaesthesia was carried out by intraperitoneal injection of ketamine. Lastly, we show that the tumour size has an influence on the tumoral uptake of radiolabelled lipiodol; therefore, this parameter must also be carefully controlled.
动脉内代谢放疗（使用用碘-131或铼-188标记的碘油）是一种可用于治疗肝细胞癌（HCC）的治疗方法。我们提出了一种使用N1-S1细胞系的肿瘤模型的详细描述以及一种动脉内注射放射性标记碘油的技术，以便进行评估新分子所需的临床前研究。我们还报告了所面临的主要技术难题。肿瘤细胞的注射速度是肿瘤诱导的关键因素，因为缓慢注射导致肿瘤诱导率为36.3%，而使用极慢注射时为76.6%（P<0.01）。因此，在肿瘤细胞的包膜下注射过程中应仔细控制该参数。此外，在注射放射性标记碘油时，不应使用异氟烷进行麻醉，因为这会导致肿瘤摄取减少。实际上，我们发现使用异氟烷时“肿瘤/健康肝脏”摄取率仅为2.1±0.7，而通过腹腔注射氯胺酮进行麻醉时为4.4±2.6（P<0.05）。最后，我们表明肿瘤大小对放射性标记碘油的肿瘤摄取有影响；因此，该参数也必须仔细控制。
